Loading...

Paratek Pharmaceuticals

Nasdaq:PRTK
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PRTK
Nasdaq
$181M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
  • Paratek Pharmaceuticals has significant price volatility in the past 3 months.
PRTK Share Price and Events
7 Day Returns
-5.9%
NasdaqGM:PRTK
-3.3%
US Pharmaceuticals
-0.3%
US Market
1 Year Returns
-48.7%
NasdaqGM:PRTK
7.1%
US Pharmaceuticals
7%
US Market
PRTK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Paratek Pharmaceuticals (PRTK) -5.9% -3.5% -14.7% -48.7% -63% -
US Pharmaceuticals -3.3% -6% -2% 7.1% 5.1% 14.4%
US Market -0.3% 2% 8.5% 7% 37.7% 46.8%
1 Year Return vs Industry and Market
  • PRTK underperformed the Pharmaceuticals industry which returned 7.1% over the past year.
  • PRTK underperformed the Market in United States of America which returned 7% over the past year.
Price Volatility
PRTK
Industry
5yr Volatility vs Market

Value

 Is Paratek Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Paratek Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Paratek Pharmaceuticals.

NasdaqGM:PRTK Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:PRTK
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.674 (1 + (1- 21%) (126.81%))
1.234
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.23
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.234 * 5.96%)
10.09%

Discounted Cash Flow Calculation for NasdaqGM:PRTK using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Paratek Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:PRTK DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.09%)
2019 -143.85 Analyst x2 -130.67
2020 -122.17 Analyst x2 -100.81
2021 -55.76 Analyst x2 -41.79
2022 74.04 Analyst x2 50.41
2023 209.86 Analyst x2 129.80
2024 352.24 Est @ 67.84% 197.90
2025 522.39 Est @ 48.31% 266.61
2026 703.32 Est @ 34.63% 326.06
2027 879.60 Est @ 25.06% 370.42
2028 1,041.12 Est @ 18.36% 398.27
Present value of next 10 years cash flows $1,466.20
NasdaqGM:PRTK DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,041.12 × (1 + 2.73%) ÷ (10.09% – 2.73%)
$14,539.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $14,539.68 ÷ (1 + 10.09%)10
$5,562.02
NasdaqGM:PRTK Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,466.20 + $5,562.02
$7,028.21
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,028.21 / 32.42
$216.81
NasdaqGM:PRTK Discount to Share Price
Calculation Result
Value per share (USD) From above. $216.81
Current discount Discount to share price of $5.57
= -1 x ($5.57 - $216.81) / $216.81
97.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Paratek Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $5.57 vs Future cash flow value of $216.81
Current Discount Checks
For Paratek Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Paratek Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Paratek Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Paratek Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Paratek Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:PRTK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.57
NasdaqGM:PRTK Share Price ** NasdaqGM (2019-04-18) in USD $5.57
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.42x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Paratek Pharmaceuticals.

NasdaqGM:PRTK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PRTK Share Price ÷ EPS (both in USD)

= 5.57 ÷ -3.57

-1.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Paratek Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Paratek Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Paratek Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:PRTK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
34.4%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.5x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Paratek Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Paratek Pharmaceuticals's assets?
Raw Data
NasdaqGM:PRTK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.47
NasdaqGM:PRTK Share Price * NasdaqGM (2019-04-18) in USD $5.57
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 3.44x
United States of America Market PB Ratio Median Figure of 5,184 Publicly-Listed Companies 1.91x
NasdaqGM:PRTK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PRTK Share Price ÷ Book Value per Share (both in USD)

= 5.57 ÷ 1.47

3.78x

* Primary Listing of Paratek Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Paratek Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Paratek Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Paratek Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Paratek Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Paratek Pharmaceuticals expected to grow at an attractive rate?
  • Paratek Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Paratek Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Paratek Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:PRTK Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:PRTK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 34.4%
NasdaqGM:PRTK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 50.1%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:PRTK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:PRTK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 347 245 174 5
2022-12-31 228 85 38 5
2021-12-31 120 -50 -105 5
2020-12-31 46 -94 -130 7
2019-12-31 15 -127 -143 7
NasdaqGM:PRTK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 17 -81 -112
2018-09-30 5 -85 -111
2018-06-30 5 -80 -101
2018-03-31 13 -73 -89
2017-12-31 13 -79 -89
2017-09-30 8 -80 -94
2017-06-30 8 -94 -96
2017-03-31 0 -101 -108
2016-12-31 0 -94 -112
2016-09-30 -86 -106
2016-06-30 -78 -106
2016-03-31 -70 -91

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Paratek Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Paratek Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:PRTK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Paratek Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PRTK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.38 4.65 2.10 2.00
2022-12-31 0.77 1.10 0.43 2.00
2021-12-31 -2.57 -1.65 -4.08 5.00
2020-12-31 -3.32 -2.35 -4.55 6.00
2019-12-31 -4.36 -3.58 -4.90 7.00
NasdaqGM:PRTK Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.57
2018-09-30 -3.66
2018-06-30 -3.42
2018-03-31 -3.14
2017-12-31 -3.32
2017-09-30 -3.66
2017-06-30 -3.95
2017-03-31 -4.93
2016-12-31 -5.51
2016-09-30 -5.61
2016-06-30 -6.00
2016-03-31 -5.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Paratek Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Paratek Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Paratek Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Paratek Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Paratek Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Paratek Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Paratek Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Paratek Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Paratek Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Paratek Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PRTK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 17.12 -112.36 63.66
2018-09-30 5.17 -111.46 50.06
2018-06-30 5.13 -100.70 44.67
2018-03-31 12.61 -89.15 40.48
2017-12-31 12.62 -89.07 36.97
2017-09-30 7.57 -93.63 31.80
2017-06-30 7.56 -95.93 29.54
2017-03-31 0.05 -108.04 28.42
2016-12-31 0.03 -111.64 26.40
2016-09-30 -106.29 25.54
2016-06-30 -106.08 25.38
2016-03-31 -91.50 22.06
2015-12-31 -70.86 19.99
2015-09-30 4.00 -61.12 16.33
2015-06-30 4.00 -41.67 12.61
2015-03-31 4.29 -28.98 9.67
2014-12-31 4.34 -19.76 5.85
2014-09-30 0.40 -11.68 4.47
2014-06-30 0.55 -11.39 3.25
2014-03-31 0.39 -10.61 2.88
2013-12-31 0.48 -11.42 3.39
2013-09-30 0.56 -36.67 9.68
2013-06-30 0.51 -40.84 9.88
2013-03-31 2.84 -45.11 10.04
2012-12-31 3.06 -49.96 10.49
2012-09-30 3.53 -27.76 4.40
2012-06-30 45.96 15.08 4.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Paratek Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Paratek Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Paratek Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Paratek Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Paratek Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Paratek Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Paratek Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Paratek Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Paratek Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Paratek Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Paratek Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:PRTK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 47.58 228.96 250.35
2018-09-30 57.63 228.68 288.25
2018-06-30 85.49 218.53 264.05
2018-03-31 110.77 59.29 184.32
2017-12-31 82.48 59.19 151.72
2017-09-30 99.87 49.08 163.44
2017-06-30 113.38 48.98 175.34
2017-03-31 84.81 39.06 139.59
2016-12-31 71.59 38.97 128.04
2016-09-30 85.47 19.65 120.79
2016-06-30 106.46 19.63 150.40
2016-03-31 73.14 19.60 112.26
2015-12-31 101.24 19.57 131.30
2015-09-30 120.22 19.54 146.43
2015-06-30 140.99 0.00 148.74
2015-03-31 84.85 0.00 92.51
2014-12-31 95.22 0.00 95.86
2014-09-30 -18.80 10.30 1.53
2014-06-30 -15.75 6.00 0.11
2014-03-31 -33.77 1.35 1.21
2013-12-31 -33.77 1.35 1.21
2013-09-30
2013-06-30
2013-03-31 -32.29 0.00 1.02
2012-12-31 -32.29 0.00 1.02
2012-09-30 -19.14 5.52 2.31
2012-06-30 -13.22 1.34 3.32
  • Paratek Pharmaceuticals's level of debt (481.2%) compared to net worth is high (greater than 40%).
  • Paratek Pharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Paratek Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Paratek Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.7% each year.
X
Financial health checks
We assess Paratek Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Paratek Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Paratek Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Paratek Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Paratek Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Paratek Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Paratek Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:PRTK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:PRTK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Paratek Pharmaceuticals has not reported any payouts.
  • Unable to verify if Paratek Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Paratek Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Paratek Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Paratek Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Paratek Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Paratek Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Paratek Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Paratek Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Bigham
COMPENSATION $3,714,883
AGE 60
TENURE AS CEO 4.8 years
CEO Bio

Mr. Michael F. Bigham, also known as Mike, CPA, MBA serves as a Partner at Datron Systems, Inc. Mr. Bigham has been the Chairman and Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 2014 served as its Executive Chair. He has been a Director of Adamas Pharmaceuticals, Inc. since September 22, 2016. He served as the Chairman of the Board of Inmediata Corp. and serves as its Director. Mr. Bigham served as an Executive Partner at Abingworth LLP since 2002 and was responsible for Abingworth’s Waltham Office and focuses on Venture Capital, Venture Growth, VIPEs (Venture Investments in Public Equities), and East Coast venture deals. Mr. Bigham served as a Partner at Abingworth LLP. Mr. Bigham had been a Director of Abingworth Management, Inc. since January 2003. He served as the Chief Executive Officer and President at Coulter Pharmaceutical, Inc. from July 1, 1996 to December 2000. Prior to joining Coulter, Mr. Bigham was employed at Gilead Sciences Inc., where he spent eight years serving in various capacities, including Executive Vice President of Operations from April 1994 to June 1996 and the Chief Financial Officer from April 1994 to June 1996. At Gilead, he also served as Vice President of Corporate Development from July 1988 to March 1992. Mr. Bigham joined as a Partner at Hambrecht & Quist LLC and became Co-Head of Healthcare Investment Banking from 1984 to 1988. He served as a Vice Chairman of Corixa Corporation. Mr. Bigham served as a Director of Avedro, Inc. until July 2015. He served as a Director of Oculex Pharmaceuticals Inc. since March 2000. Mr. Bigham served as a Director of Hydra Biosciences, Inc., Celgene Avilomics Research, Inc. (Avila Therapeutics Inc.) and Magellan Diagnostics, Inc. He served as a Director of Xenogen Corporation since July 2003, LJL BioSystems, Inc. since June 1997 and Datron Systems, Inc. since May 1996. Mr. Bigham served as a Director of Supernus Pharmaceuticals Inc. from February 22, 2006 to December 23, 2013. He served as Director of Syntaxin Ltd. and Valeritas, Inc. Mr. Bigham served as a Director of Dynogen Pharmaceuticals, Inc. since May 1996, Corixa Corp. since December 2000, PrimeraDx, Inc. until September 2009, Coulter Pharmaceutical, Inc. from July 1996 to December 2000 and Edusa Pharmaceuticals, Inc. since 1996. He served as an Observer of Portola Pharmaceuticals, Inc. Mr. Bigham served as a Director of Intrabiotics Pharmaceuticals Inc. and Portola Pharmaceuticals, Inc. He has 14 years of operational experience and six years investment banking experience in life science companies. Mr. Bigham is a C.P.A. He holds a B.S. degree, with distinction, in Commerce from the University of Virginia and holds an M.B.A. from the Stanford Graduate School of Business.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Paratek Pharmaceuticals management team in years:

3.8
Average Tenure
53.5
Average Age
  • The tenure for the Paratek Pharmaceuticals management team is about average.
Management Team

Mike Bigham

TITLE
Chairman & CEO
COMPENSATION
$4M
AGE
60
TENURE
4.8 yrs

Evan Loh

TITLE
President
COMPENSATION
$3M
AGE
59
TENURE
4.8 yrs

Bill Haskel

TITLE
Senior VP
COMPENSATION
$2M
AGE
56
TENURE
3.8 yrs

Adam Woodrow

TITLE
Chief Commercial Officer & VP
COMPENSATION
$2M
AGE
51
TENURE
4.5 yrs

Doug Pagán

TITLE
Consultant
COMPENSATION
$2M
AGE
46

Sarah Higgins

TITLE
VP, Controller and Interim Principal Financial & Accounting Officer
AGE
43

Randy Brenner

TITLE
Senior Vice President of Regulatory
TENURE
2.3 yrs

Ben Strain

TITLE
Executive Director of Investor Relations & Corporate Communications

Judith Steenbergen

TITLE
Vice President of Medical Strategy & Communications
TENURE
1.3 yrs

Christine Coyne

TITLE
Vice President of Marketing
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Paratek Pharmaceuticals board of directors in years:

4.5
Average Tenure
59
Average Age
  • The tenure for the Paratek Pharmaceuticals board of directors is about average.
Board of Directors

Evan Loh

TITLE
President
COMPENSATION
$3M
AGE
59
TENURE
6.9 yrs

Tom Dietz

TITLE
Outside Director
COMPENSATION
$240K
AGE
54
TENURE
4.5 yrs

Mike Bigham

TITLE
Chairman & CEO
COMPENSATION
$4M
AGE
60
TENURE
4.8 yrs

Jeff Stein

TITLE
Director
COMPENSATION
$215K
AGE
63
TENURE
4.5 yrs

Bob Radie

TITLE
Outside Director
COMPENSATION
$210K
AGE
55
TENURE
4.5 yrs

Tim Franson

TITLE
Outside Director
COMPENSATION
$206K
AGE
66
TENURE
3.8 yrs

Kris Peterson

TITLE
Outside Director
COMPENSATION
$208K
AGE
59
TENURE
3.1 yrs

Rolf Hoffmann

TITLE
Director
AGE
59
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • Paratek Pharmaceuticals insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
07. Feb 19 Sell Adam Woodrow Individual 05. Feb 19 05. Feb 19 -3,331 $6.77 $-22,551
26. Dec 18 Sell Thomas Dietz Individual 21. Dec 18 21. Dec 18 -9,330 $5.01 $-46,743
14. Dec 18 Sell William Haskel Individual 13. Dec 18 13. Dec 18 -1,000 $6.25 $-6,250
14. Dec 18 Sell Evan Loh Individual 13. Dec 18 13. Dec 18 -6,000 $6.27 $-37,620
X
Management checks
We assess Paratek Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Paratek Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Does Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Affect Your Portfolio Volatility?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Poised For Long-Term Success?

Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) latest earnings update in December 2018 … that losses became smaller relative to the prior year's level

Simply Wall St -

Imagine Owning Paratek Pharmaceuticals While The Price Tanked 59%

And over the last year the share price fell 51%, so we doubt many shareholders are delighted. … The falls have accelerated recently, with the share price down 14% in the last three months. … Given that Paratek Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development.

Simply Wall St -

What Kind Of Shareholders Own Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)?

Generally speaking, as a company grows, institutions will increase their ownership. … Taking a look at the our data on the ownership groups (below), it's seems that. … We can zoom in on the different ownership groups, to learn more about PRTK

Simply Wall St -

Is Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) CEO Overpaid Relative To Its Peers?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mike Bigham's Compensation Compare With Similar Sized Companies. … While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$460k.

Simply Wall St -

How Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Can Impact Your Portfolio Volatility

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Paratek Pharmaceuticals Inc (NASDAQ:PRTK): Time For A Financial Health Check

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) is a small-cap stock with a market capitalization of US$327.02m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is

Simply Wall St -

When Can We Expect A Profit From Paratek Pharmaceuticals Inc (NASDAQ:PRTK)?

Paratek Pharmaceuticals Inc's (NASDAQ:PRTK):. … Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. … The US$336.50m market-cap posted a loss in its most recent financial year of -US$89.07m and a latest trailing-twelve-month loss of -US$89.15m leading to an even wider gap between loss and breakeven

Simply Wall St -

Where Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Stands In Terms Of Earnings Growth Against Its Industry

NasdaqGM:PRTK Income Statement Mar 1st 18 We can further assess Paratek Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years Paratek Pharmaceuticals has seen an annual decline in revenue of -52.10%, on average. … This means even though Paratek Pharmaceuticals is currently running a loss, it may have been aided by industry tailwinds, moving earnings into a more favorable position.What does this mean?

Simply Wall St -

February Best Growth Stocks

PRTK’s projected future profit growth is a robust 36.13%, with an underlying triple-digit growth from its revenues expected over the upcoming years. … NasdaqGM:PRTK Future Profit Feb 14th 18 Kush Bottles, Inc. … NasdaqCM:ESES Future Profit Feb 14th 18 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

Company Info

Description

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Details
Name: Paratek Pharmaceuticals, Inc.
PRTK
Exchange: NasdaqGM
Founded: 1996
$180,556,991
32,415,977
Website: http://paratekpharma.com
Address: Paratek Pharmaceuticals, Inc.
75 Park Plaza,
4th Floor,
Boston,
Massachusetts, 02116,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PRTK Common Stock Nasdaq Global Market US USD 31. Oct 2014
DB N4CN Common Stock Deutsche Boerse AG DE EUR 31. Oct 2014
Number of employees
Current staff
Staff numbers
103
Paratek Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 00:24
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.